References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117-28
- Howlader N, Noone AM, Krapcho M, et al.; SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). 2011. http://seer.cancer.gov/csr/1975_2009_pops09/results_merged/sect_06_colon_rectum.pdf. Accessed March 6, 2013
- Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83
- Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012;2012:406830 . doi: 10.1155/2012/406830. Epub 2012 May 17
- Genentech Inc. Avastin® (bevacizumab). Prescribing information. 2013. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed March 6, 2013
- Bristol-Myers Squibb. Erbitux® (cetuximab) prescribing information. 2012. http://packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed March 6, 2013
- Amgen I. Vectibix® (panitumumab) presribing information. 2013. http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf. Accessed March 6, 2013
- Bayer HealthCare Pharmaceuticals IncBayer HealthCare Pharmaceuticals I. Stivarga (regorafenib). Prescribing information. 2013. http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf. Accessed March 6, 2013
- Regeneron Pharmaceuticals I. Zaltrap® (ziv-aflibercept). Prescribing information. 2012. http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf. Accessed March 6, 2013
- Liang SY, Phillips KA, Wang G, et al. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care 2011;49:e1-8
- Lund JL, Sturmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care 2013;51:e27--34
- Yang H, Yu AP, Wu EQ, et al. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ 2011;14:542-52
- Hess GP, Wang PF, Quach D, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 2010;6:301-7
- US Department of Health and Human Services. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. http://www.cms.gov/Regulations-and-Guidance/HIPAA-Administrative-Simplification/HIPAAGenInfo/TheHIPAALawandRelated-Information.html. Accessed March 6, 2013
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidlines in oncology. Colon cancer. Version 3. 2013. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed March 6, 2013
- US Department of Labor BoLS. Consumer Price Index. Chained Consumer Price Index. 2010. http://data.bls.gov/cgi-bin/surveymost?su. Accessed March 6, 2013
- Song X, Zhao Z, Barber B, et al. Characterizing medical care by disease phase in metastatic colorectal cancer. Am J Manag Care 2011;17(Suppl 5):SP20-5
- Zafar SY, Marcello JE, Wheeler JL, et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009;5:228-33
- Ferro SA, Myer BS, Wolff DA, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008;14:717-25